Cancer, immune drugmakers dominate VC funding so far in 2026
www.biopharmadive.comSix of the 13 venture-backed biotech companies to price an initial public offering in 2026 are testing drugs for cancer or immune conditions, including the year’s biggest IPO to date, Parabilis, which banked $670 million in its June debut.
Focus Sectors
BioTechHealthTechcommon.sector.deeptech
Investment Stage
SeedSeries A